Dépistage prénatal de la trisomie 21 par les marqueurs sériques : expérience tunisienne
| Autor: | H. Chahed, H. Khairi, Y. Chaabouni, A. Miled, N. Saafi, S. Ferchichi, Sandrine Laradi, H.B. Limem, M. Bernard, Z. Jaidane, M. Sakouhi |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Diminution
Gynecology Down syndrome medicine.medical_specialty Pregnancy business.industry Biochemistry (medical) Clinical Biochemistry Aneuploidy medicine.disease Endocrinology Internal medicine Immunopathology medicine Alpha-fetoprotein business Oncofetal antigen Trisomy reproductive and urinary physiology |
| Zdroj: | Immuno-analyse & Biologie Spécialisée. 25:205-211 |
| ISSN: | 0923-2532 |
| Popis: | Summary Maternal marker screening for Down's syndrome is based on an individual risk calculation obtained by weighting the risk due to maternal age by a factor linked to maternal serum markers. The maternal serum markers used in our study are alpha-fetoprotein (AFP) and human chorionic gonadotrophin (hCG), previously known of their efficiency at the second trimester. The AFP and hCG were measured for 241 pregnant women, recruited in the maternity units of the center of Tunisia. The age of pregnancy was known for only 163 women. Using the 1/250 cut off for this double test, only one woman has presented a high risk for Down's syndrome (1/32). The foetal karyotyping was performed and chromosomal abnormality was confirmed. This computerized program allowed us to detect 7.46% of neural tube defects. In addition we found 3.7 % of cases with decrease of hCG demonstrating diminution of foetal viability. It would be desirable to generalize prenatal screening for Down's syndrome to all pregnant women regardless of their age through the use of serum markers in the maternal blood. The dissemination of this double test will limit the use of invasive examinations. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect